Corcept Therapeutics (CORT) Revenue & Revenue Breakdown
Corcept Therapeutics Revenue Highlights
Latest Revenue (Y)
$482.38M
Latest Revenue (Q)
$163.80M
Corcept Therapeutics Revenue by Period
Corcept Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $482.38M | 20.04% |
| 2022-12-31 | $401.86M | 9.80% |
| 2021-12-31 | $365.98M | 3.42% |
| 2020-12-31 | $353.87M | 15.46% |
| 2019-12-31 | $306.49M | 21.99% |
| 2018-12-31 | $251.25M | 57.82% |
| 2017-12-31 | $159.20M | 95.77% |
| 2016-12-31 | $81.32M | 61.72% |
| 2015-12-31 | $50.29M | 89.39% |
| 2014-12-31 | $26.55M | 156.36% |
| 2013-12-31 | $10.36M | 213.18% |
| 2012-12-31 | $3.31M | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | -100.00% |
| 2009-12-31 | $29.00K | -86.12% |
| 2008-12-31 | $209.00K | -56.64% |
| 2007-12-31 | $482.00K | 63.95% |
| 2006-12-31 | $294.00K | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | 100.00% |
| 2001-12-31 | - | - |
Corcept Therapeutics generated $482.38M in revenue during NA 2023, up 20.04% compared to the previous quarter, and up 191.99% compared to the same period a year ago.
Corcept Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $163.80M | 11.57% |
| 2024-03-31 | $146.81M | 8.42% |
| 2023-12-31 | $135.41M | 9.55% |
| 2023-09-30 | $123.60M | 5.00% |
| 2023-06-30 | $117.72M | 11.42% |
| 2023-03-31 | $105.65M | 2.52% |
| 2022-12-31 | $103.06M | 1.31% |
| 2022-09-30 | $101.73M | -1.60% |
| 2022-06-30 | $103.39M | 10.35% |
| 2022-03-31 | $93.69M | -5.20% |
| 2021-12-31 | $98.82M | 2.80% |
| 2021-09-30 | $96.13M | 4.96% |
| 2021-06-30 | $91.59M | 15.30% |
| 2021-03-31 | $79.44M | -7.35% |
| 2020-12-31 | $85.73M | -0.69% |
| 2020-09-30 | $86.33M | -2.53% |
| 2020-06-30 | $88.56M | -5.02% |
| 2020-03-31 | $93.25M | 6.09% |
| 2019-12-31 | $87.89M | 7.84% |
| 2019-09-30 | $81.50M | 12.80% |
| 2019-06-30 | $72.26M | 11.46% |
| 2019-03-31 | $64.83M | -3.00% |
| 2018-12-31 | $66.83M | 3.70% |
| 2018-09-30 | $64.44M | 3.42% |
| 2018-06-30 | $62.31M | 8.07% |
| 2018-03-31 | $57.66M | 8.22% |
| 2017-12-31 | $53.28M | 24.59% |
| 2017-09-30 | $42.76M | 20.26% |
| 2017-06-30 | $35.56M | 28.84% |
| 2017-03-31 | $27.60M | 15.90% |
| 2016-12-31 | $23.81M | 9.61% |
| 2016-09-30 | $21.73M | 10.15% |
| 2016-06-30 | $19.72M | 22.81% |
| 2016-03-31 | $16.06M | 7.31% |
| 2015-12-31 | $14.97M | 12.86% |
| 2015-09-30 | $13.26M | 10.92% |
| 2015-06-30 | $11.96M | 18.35% |
| 2015-03-31 | $10.10M | 12.07% |
| 2014-12-31 | $9.01M | 23.78% |
| 2014-09-30 | $7.28M | 24.46% |
| 2014-06-30 | $5.85M | 32.83% |
| 2014-03-31 | $4.41M | 7.05% |
| 2013-12-31 | $4.12M | 56.23% |
| 2013-09-30 | $2.63M | 39.29% |
| 2013-06-30 | $1.89M | 10.13% |
| 2013-03-31 | $1.72M | 24.69% |
| 2012-12-31 | $1.38M | 30.52% |
| 2012-09-30 | $1.05M | 20.57% |
| 2012-06-30 | $875.00K | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | -100.00% |
| 2009-06-30 | $6.00K | -75.00% |
| 2009-03-31 | $24.00K | -83.22% |
| 2008-12-31 | $143.00K | 116.67% |
| 2008-09-30 | $66.00K | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | - |
Corcept Therapeutics generated $163.80M in revenue during Q2 2024, up 11.57% compared to the previous quarter, and up 155.03% compared to the same period a year ago.
Corcept Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HALO | Halozyme Therapeutics | $829.25M | $231.35M |
| CORT | Corcept Therapeutics | $482.38M | $163.80M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| INSM | Insmed | $305.21M | $90.34M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.62M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| FIXX | Q32 Bio | $1.16M | - |
| KRTX | Karuna Therapeutics | $654.00K | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| DICE | DICE Therapeutics | - | - |
| NXTC | NextCure | - | - |
| DYN | Dyne Therapeutics | - | - |
| GRPH | LENZ Therapeutics | - | - |
| CERE | Cerevel Therapeutics | - | - |
| ERAS | Erasca | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| SNSE | Sensei Biotherapeutics | - | - |
| MACK | Merrimack Pharmaceuticals | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
CORT Revenue FAQ
What is Corcept Therapeutics’s yearly revenue?
Corcept Therapeutics's yearly revenue for 2023 was $482.38M, representing an increase of 20.04% compared to 2022. The company's yearly revenue for 2022 was $401.86M, representing an increase of 9.80% compared to 2021. CORT's yearly revenue for 2021 was $365.98M, representing an increase of 3.42% compared to 2020.
What is Corcept Therapeutics’s quarterly revenue?
Corcept Therapeutics's quarterly revenue for Q2 2024 was $163.8M, a 11.57% increase from the previous quarter (Q1 2024), and a 39.15% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $146.81M, a 8.42% increase from the previous quarter (Q4 2023), and a 38.95% increase year-over-year (Q1 2023). CORT's quarterly revenue for Q4 2023 was $135.4M, a 9.55% increase from the previous quarter (Q3 2023), and a 31.39% increase year-over-year (Q4 2022).
What is Corcept Therapeutics’s revenue growth rate?
Corcept Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 31.80%, and for the last 5 years (2019-2023) was 57.39%.